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Liposomes have been extensively used as eﬀective nanocarriers, providing better solubility,
higher stability and slower release of drugs compared to free drug administration. They
are also preferred due to their nontoxic nature as well as their biodegradability and cell
membrane mimicking abilities. In this study, we examined noncovalent integration of a
cell penetrating arginine-rich peptide amphiphile into a liposomal formulation
of negatively charged 1,2-dioleoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (DOPG)
phospholipids in the presence of cholesterol due to its amphipathic character. We
studied changes in the physical characteristics (size, surface potential and membrane
polarity) of the liposomal membrane, as well as in the encapsulation of hydrophilic and
hydrophobic agents due to peptide amphiphile incorporation. The activities of peptide
integrated liposomal systems as drug delivery agents were investigated by using anti-
cancer drugs, doxorubicin-HCl and paclitaxel. Enhancement in liposomal uptake due to
arginine-rich peptide integration, and enhanced eﬃcacy of the drugs were observed
with peptide functionalized liposomes compared to free drugs.Introduction
Liposomes have been considered as potential drug delivery agents for several
decades due to their biocompatibility, biodegradability and their resemblance to
cell membrane.1 Self-organization of lipid molecules into bilayer structures in
aqueous environments through their amphipathic character results in the
formation of spherical vesicles.2 Their versatile nature enables the design of
various functional liposomal systems decorated with a wide range of bioactive
molecules such as antibodies, viral proteins, carbohydrates, peptides, aptamers,Institute of Materials Science and Nanotechnology, National Nanotechnology Research Center (UNAM), Bilkent
University, Ankara, Turkey. E-mail: moguler@unam.bilkent.edu.tr; atekinay@unam.bilkent.edu.tr; Fax: +90
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View Article Onlineand vitamins for therapeutic delivery.3,4 Various approaches have been used to
functionalize liposomes including chemical coupling of the lipid molecules or
ligand of interest before liposome formation, covalent conjugation of biologically
active segments to the liposome surface and noncovalent association of liposome
constituents.5–7
Amphiphilic peptides comprised of a bioactive peptide sequence and a
hydrophobic segment have great potential for the functionalization of liposomal
carriers. They can be designed and chemically synthesized with high yield and
specicity and more importantly, they can be easily incorporated into liposomes
noncovalently due to their lipid-like amphipathic properties with minimized
activity loss or without laborious chemical functionalization steps.8–11 The ease of
functionalization together with their extensive encapsulation capacity make them
attractive tools for the development of carrier systems, which can deliver cargo to
the target with enhanced in vivo stability and circulation time.12 Besides their
facile integration, the versatility of peptide sequences provides diverse bio-
functionality to the liposomal carriers.
The importance of cell penetrating peptides including HIV-Tat derived
peptides, oligoarginines, and chimeric cell penetrating peptides has been
emphasized in several studies for the delivery of therapeutic agents to target
cells.13,14 Arginine-rich peptides have also been synthesized and investigated for
enhanced cellular uptake eﬃciency by conjugation of fatty acids.15
Herein, we designed and synthesized an arginine-rich, cell penetrating peptide
amphiphile molecule and examined its integration into a liposomal formulation
of 1,2-dioleoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (DOPG) phospholipid in the
presence of cholesterol. We studied the size, surface potential, and membrane
polarity of the resulting liposomes with and without peptide amphiphile incor-
poration. Encapsulation capacities of these carriers were examined by using
hydrophilic and hydrophobic dyes, rhodamine B and Nile red, respectively. Aer
optimization of the encapsulation eﬃciencies of the liposomes, the in vitro uptake
proles and cytotoxicities of cancer drugs including doxorubicin-HCl and pacli-
taxel entrapped in liposomes with and without peptide amphiphile molecules
were examined on the MCF7 human breast cancer cell line.Experimental
Materials
9-Fluorenylmethoxycarbonyl (Fmoc) and tert-butoxycarbonyl (Boc) protected
amino acids, [4-[a-(20,40-dimethoxyphenyl) Fmoc-aminomethyl]phenoxy]acet-
amidonorleucyl-MBHA resin (Rink amide MBHA resin), and 2-(1H-benzotriazol-1-
yl)-1,1,3,3 tetramethyluronium hexauorophosphate (HBTU) were purchased
from NovaBiochem and ABCR. Lauric acid was purchased from Merck. 1,2-dio-
leoyl-sn-glycero-3-[phosphor-rac-(1-glycerol)] (DOPG) was purchased from Avanti
Polar Lipids. Other chemicals were purchased from Alfa Aesar, Sigma-Aldrich or
Applichem and used as provided.Synthesis and characterization of peptide amphiphile molecule
The lauryl–PPPPRRRR–Am peptide amphiphile (PA) molecule was synthesized on
MHBA Rink Amide resin. Amino acid couplings were performed with 2270 | Faraday Discuss., 2013, 166, 269–283 This journal is ª The Royal Society of Chemistry 2013
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View Article Onlineequivalents of Fmoc protected amino acid, 1.95 equivalents of HBTU and 3
equivalents of N,N-diisopropylethylamine (DIEA) in DMF for 3 h. Fmoc removal
was performed with 20% piperidine/dimethylformamide (DMF) solution for
20 min. Cleavage of the peptides from the resin was carried out with a mixture of
triuoroacetic acid (TFA) : triisoproplysilane (TIS) : water in the ratio 95 : 2.5 : 2.5
for 2 h. Excess TFA was removed by rotary evaporation. The remaining viscous
peptide solution was treated with ice-cold diethyl ether and the resulting white
pellet was freeze-dried. The peptide amphiphiles were identied and analysed by
reverse phase HPLC on an Agilent 6530 accurate-Mass Q-TOF LC-MS equipped
with an ESI source. An Agilent Zorbax SB-C8 4.6 mm  100 mm column as the
stationary phase and a water/acetonitrile gradient with 0.1% volume of formic
acid as the mobile phase were used to identify peptide amphiphile molecules.
Liposome preparation
Liposomes were prepared via the curvature tuned preparation method reported
previously.16 DOPG:Chol and PA integrated (DOPG:Chol:PA) liposomes were
prepared with 1 : 1 and 7 : 8 : 1 molar ratios, respectively. Also, a DOPG:Chol:PA
liposome with 7.5 : 8 : 0.5 formulation was prepared to evaluate the eﬀect of
peptide amphiphile density on the cellular uptake. For all liposomal formula-
tions, 25 mg of total mixture was used. Samples were rehydrated in PBS buﬀer
(10 mM, pH 7.4, 3% glycerol, with and without encapsulated material) at 65 C
under a nitrogen supply while the mixture was continuously stirred. The solution
was treated with a rapid pH jump (pH 7.4 to pH 11 and to pH 7.4) carried out with
an equilibrium period of 25 min, in which lipid clusters curled into encapsulating
nanosized liposomes. The resulting liposomes were puried by using a G50
Sephadex column and stored at 4 C.
Zeta-potential and dynamic light scattering measurements
Themean diameters and zeta-potentials of the liposomes were measured by using
a Malvern ZetaSizer Nano-ZS ZEN 3600 (Malvern Instruments, USA) instrument
with detector angle of 173. Standard deviations were calculated from the mean of
the data from a series of experiments (n $ 3). Zeta potential measurements were
carried out using a dip cell electrode in quartz cuvettes.
Transmission electron microscopy
Using a glass pipette, a drop of sample was placed on a 200 mesh formvar coated
copper grid and carefully dried using lter paper. The sample was incubated at
room temperature until a dried lm was obtained. For PA free liposome, the
sample was stained with 2 wt% phosphotungstic acid. Transmission electron
microscope (TEM) imaging was performed by using a TEM (FEI Tecnai G2 F30)
operated at 100 keV.
Quantication of the membrane integrated peptide amphiphile molecules
The protein concentration determination procedure provided by Thermo Scien-
tic was utilized to measure the absorbance at 205 nm with an extinction coef-
cient of 31 mg mL1 at a 1 cm path length. The peptide amphiphile solutions
were prepared in 0.6 mg mL1 concentrations. Free peptide amphiphileThis journal is ª The Royal Society of Chemistry 2013 Faraday Discuss., 2013, 166, 269–283 | 271
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View Article Onlinemolecules were removed by using Millipore Microcon Centrifugal Filter Units,
with 50K MW cut-oﬀ. The retained sample was collected in each step and the
peptide amphiphile concentration was measured by a Thermo Scientic Nano-
Drop 2000 instrument. The amount of peptide amphiphile integrated into the
liposomal membrane was then calculated by subtracting the amount of free PA
from the initial PA concentration. This result was later used for calculation of the
number of peptide amphiphiles per liposome.Encapsulation capacities of liposomes
Rhodamine B was used as a model dye for hydrophilic molecules and encapsu-
lated as described in the liposome preparation procedure. Free rhodamine B
molecules were removed by using Millipore Microcon Centrifugal Filter Units,
with 50K MW cut-oﬀ. The rhodamine B concentration was determined by uo-
rescence measurements (lexc ¼ 540 nm, lem ¼ 575 nm) following destruction of
the liposome integrity by addition of ethanol (100 mL in 1900 mL ethanol) The total
encapsulation eﬃciency was then calculated by E (%) ¼ (measured intensity/
initial dye intensity)  100. Concentrations were calculated from a previously
prepared standard curve. The same procedure was followed for a hydrophilic
drug, doxorubicin-HCl, which was encapsulated with an initial concentration of
0.2mgmL1. The standard curve was obtained by using the uorescence intensity
of doxorubicin-HCl (lexc ¼ 480 nm and lem ¼ 588 nm)
Nile red was used as a model dye for hydrophobic drugs. A 1.5 mM Nile red
stock solution was prepared in ethanol and further diluted in water to 0.01 mM.
Nile red uorescence intensity maxima switch with respect to the polarity of the
environment and thus Nile red solubility in diﬀerent types of liposomes was
measured and compared in formulations of liposomes with and without peptide
amphiphile molecules. The nal concentration of 3 mM Nile red was introduced
into the liposome dispersions by the addition of 450 mL of stock solution into
1.05 mL of diluted liposome (2.5 mg mL1) or PBS. The samples were le to
equilibrate for 24 h at 4 C before the measurements. The uorescence intensity
of liposomes in PBS (lexc¼ 520 nm, lem¼ 525–700 nm) was measured by a Varian
Eclipse Fluorescence Spectrophotometer to determine the micellar character. The
encapsulation of Nile red was studied by measuring the increased emission
(lexc ¼ 476 nm, lem ¼ 633 nm) following the administration of 0.53 mM Nile red
to previously prepared PA integrated and PA free liposomes. Liposomes were lysed
by suspending 100 mL of sample in 1900 mL of ethanol and the amount of
encapsulated Nile red was calculated by using a standard curve obtained using
known concentrations of Nile red. For the hydrophobic drug model (paclitaxel),
HPLC analysis optimized by Wang et al.17 was used to measure the encapsulation
eﬃciencies of liposome formulations. Paclitaxel was extracted from the liposomes
with acetonitrile (100 mL of liposome in 900 mL acetonitrile), then ltered with a
0.2 mm syringe lter and the concentration was analysed by using HPLC-1200S
(Agilent). A 10 mL sample solution was injected into an Eclipse XDB-C18 (4.6 
150 mm, 5 mm) column. Water and acetonitrile (53 : 47) were used as the mobile
phase. The elution rate was set to 1.0 mL min1 and the paclitaxel detection
wavelength was 229 nm. The number of integrated peptide amphiphiles and the
amount of encapsulated material per liposome were calculated and the details of
the related calculations can be found in the ESI.†272 | Faraday Discuss., 2013, 166, 269–283 This journal is ª The Royal Society of Chemistry 2013
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View Article OnlineIn vitro release of rhodamine B
In vitro release of the hydrophilic rhodamine B from liposomes was studied in
10% FBS containing PBS medium.17 Rhodamine B encapsulated liposomes were
placed in a dialysis bag (Spectra/Por membrane MWCO 500–1000 Da, 24 mm at
width, Spectrum Medical Industries, Los Angeles, CA) and released rhodamine B
was collected in 50 mL PBS (pH 7.4 and pH 5.5) at 37 C. 1 mL aliquots of dialysis
solution were removed and replaced by equal volumes of fresh buﬀer solution at
37 C. Rhodamine B release was measured by a Cary Eclipse uorescence spec-
trophotometer for 72 h (lexc ¼ 540 nm, lem ¼ 575 nm).Cytotoxicity studies
The cytotoxicity was evaluated by using the Alamar Blue assay. MCF7 cells were
incubated in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin
under 5% CO2 at 37 C. Cells were cultured in a 96-well plate in 200 mL of medium
per well with a density of 8  103 cells per well for 24 h. 50 mL of liposome with or
without peptide formulation was administered with peptide concentrations of
250 mM, 25 mM and 12.5 mM (n ¼ 4 for all groups). Aer 4 h and 24 h of treatment,
the culture medium was replaced with serum free DMEM supplemented with 1%
penicillin/streptomycin and 10% Alamar Blue solutions and the samples were
incubated for an additional 4 h. Cell viability was quantied by measuring the
uorescence with excitation at 540 nm and emission at 590 nm with a microplate
reader (Molecular Devices Spectramax M5).In vitro uptake of peptide integrated liposomes
MCF7 cells were seeded at a density of 3  104 cells per well in 24 well plates.
100 mL of liposome formulation was then administered and a 500 mL total culture
volume was achieved. For rhodamine B loaded liposomes, administration was
optimized to a nal rhodamine B concentration of 4.5 mM. Aer 3 h of incubation,
the culture medium was removed and the cells were washed two times with PBS.
Then, the cells were lysed by using 100 mL of 0.5 M NaOH for 15 min with vigorous
shaking in the dark. Lysates were collected and centrifuged at 15 000 rpm for
5 min. The rhodamine B concentration was measured from the supernatant by
uorescence measurements by a Nanodrop 3300 (lexc ¼ 540 nm, lem ¼ 590 nm).
The uorescence intensity was normalized to the protein concentrations of the
total cell extracts in order to calculate the relative uptake. The protein concen-
tration of the lysates was measured by the Bradford protein assay (Roche). In the
case of Nile red loaded liposomes, the sample concentrations were adjusted to
obtain 10 mM of nal Nile red. Aer 3 h of incubation with Nile red loaded
liposomes or free Nile red, the cells were washed as described above and lysed
with 300 mL of 90 : 10 (v/v) ethanol : water for 15min with vigorous shaking. Then,
the lysates were centrifuged and uorescence of the supernatant was measured
(lexc ¼ 476 nm, lem ¼ 633 nm).Fluorescence microscopy
MCF7 cells were seeded at a density of 1  104 cells per well in 24 well plates.
100 mL of sample solution was administered with Nile red at 10 mM. Following
24 h of incubation, the cells were washed two times with PBS and they wereThis journal is ª The Royal Society of Chemistry 2013 Faraday Discuss., 2013, 166, 269–283 | 273
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View Article Onlinedirectly mounted onto glass slides. 100 and 200 images were recorded by a
Zeiss AxioCam uorescence microscope. All imaging parameters were same for
all of the experimental groups.In vitro drug cytotoxicity: time and dose response
The in vitro drug cytotoxicity of the doxorubicin-HCl and paclitaxel formulations
were evaluated by using the Alamar Blue assay. MCF7 cells were cultured in 96-
well plates at a cell density of 8 103 (for doxorubicin-HCl treatment) and 4 103
(for paclitaxel treatment) cells per well. Then, the cells were treated with drug
loaded liposomes and free drug for another 24 h. Aer rinsing the cells with fresh
media, the viability of the cells was quantied via the Alamar Blue assay. The cells
were exposed to drug loaded liposomes or free drug for 1, 3 or 6 h, and the nal
drug concentrations were adjusted to 10 mM for doxorubicin-HCl and 30 mM for
paclitaxel. Then, the cells were rinsed two times with fresh medium and incu-
bated in standard cell culture medium for 24 h. Finally, the cytotoxicity levels and
inhibition of cell proliferation were determined by the Alamar Blue assay.Statistical analysis
All data are presented with the standard error of the mean (mean  SEM). One-
way or two-way analysis of the variance (ANOVA) was used to determine the
signicance of diﬀerences between the groups. Diﬀerences are considered
signicant when p < 0.05.Results and discussion
Synthesis and characterization of liposomes
Cell penetrating arginine-rich peptide amphiphile integrated and bare liposomes
were prepared according to the curvature tuned liposome preparation (CTLP)
method, where phospholipid residues are forced to be ordered in a nanostructure
with the synergistic eﬀect of a sudden pH jump and constant temperature.16
Addition of an amphiphilic molecule to the liposomal membrane can change the
uidity and curvature of the membrane, as well as the physical properties of the
resulting liposome such as particle size, zeta potential and morphology. In this
study, the negatively charged phospholipid DOPG was used as the main
component of the liposomes.18 Previously, it was observed that DOPG liposomes
prepared by the CTLP methodology with a size of 20 nm in diameter were not
large enough to develop an eﬃcient drug delivery system.19 Therefore, cholesterol
was incorporated into the formulation to reduce the membrane curvature, which
resulted in the formation of larger liposomes and provided intermediate
membrane uidity and prolonged circulation time.20 As shown in Table S1,† we
obtained uniform liposomes 63.5 8.2 nm in diameter with a net negative charge
of41.4 3.9 mV when the liposomes were formed by DOPG and cholesterol at a
molar ratio of 50 : 50. Transmission electron microscopy images revealed that the
resulting liposomes were unilamellar (Fig. S1†).
Liposome functionalization with cell penetrating peptides can be achieved by
chemical conjugation of a peptide to the lipids before liposome preparation or
directly to the liposome surface. Both strategies not only require additional steps
and decrease the peptide integration eﬃciency but might also result in the loss of274 | Faraday Discuss., 2013, 166, 269–283 This journal is ª The Royal Society of Chemistry 2013
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View Article Onlinebiological activity.21 Therefore, developing noncovalent strategies is desirable to
avoid chemical modications.22 The use of amphiphilic peptides is a promising
approach due to their resemblance to phospholipids.23 Therefore, we designed
and synthesized an arginine-rich peptide amphiphile molecule consisting of a
lauryl group and arginine-rich peptide sequence, lauryl–PPPPRRRR–Am, (Scheme
1 and Fig. S2†). Aer peptide amphiphile integration, the particle sizes of the
liposomes were measured to be 95.26  7.03 nm and the membrane zeta-
potential increased to 30.4 mV from 41.4 mV due to the positive net charge
possessed by the peptide amphiphile molecule (Table S1 and Fig. S1†). The
particle size of the liposomes stored at 4 C was monitored, and no signicant
change was observed in the samples for over 3 weeks.
The amount of peptide molecules incorporated into the liposomal membrane
was calculated by measuring the absorbance of the free peptide molecules
collected during the purication process.24 As shown in Table S1,† about four
thousand peptide amphiphile molecules were estimated to be integrated per
liposome. The peptide amphiphile insertion was also monitored by uorescence
assay by using Nile red as a polarity sensitive probe.25 Nile red dispersion is
usually colourless in aqueous conditions; however, changes in the environment of
the hydrophobic dye revealed a switch from polar to nonpolar in the presence ofScheme 1 (A) Chemical structures of peptide amphiphile (PA) lauryl–PPPPRRRR–Am, negatively
charged phospholipid 1,2-dioleoyl-sn-glycero-3-phospho-(10-rac-glycerol) (DOPG) and cholesterol. (B)
Transmission electronmicroscopy image of PA integrated DOPG:Chol liposomes (scale bar¼ 100 nm). (C)
Schematic representation for the preparation of PA integrated liposomes loaded with hydrophobic (Nile
red, paclitaxel) or hydrophilic (rhodamine B, doxorubicin-HCl) molecules.
This journal is ª The Royal Society of Chemistry 2013 Faraday Discuss., 2013, 166, 269–283 | 275
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View Article Onlinephospholipid and caused increased uorescence emission. In the case of peptide-
integrated liposomes, a blue shi was observed indicating a slight decrease in
membrane polarity (Fig. S3†). The size and zeta-potential results also conrmed
that peptide amphiphile molecules were embedded into the liposomal
membrane, and increased the nonpolar character of the membrane, which can be
considered as an advantage for the encapsulation of hydrophobic molecules.
Encapsulation of model reagents
Rhodamine B, a hydrophilic uorescent dye, was used to probe the encapsulation
capacities of liposomes prepared with and without peptide amphiphile mole-
cules. Rhodamine B was administered during the liposome preparation and it
was observed that the initial rhodamine B concentration aﬀected the encapsu-
lation capacities of the liposomes. Although the encapsulated dye concentration
decreased slightly from 36.3 mM to 30.5 mM aer PA integration, they encap-
sulated almost four times more rhodamine B compared to PA free liposomes due
to their larger internal volume (Table S2†). To understand the eﬀect of PA inte-
gration on the in vitro release of the entrapped rhodamine B, liposomes sus-
pended in 10% FBS containing PBS medium were dialyzed at pH 5.5 and pH 7.4
against PBS at 37 C. As shown in Fig. S4,† DOPG:Chol:PA liposomes were stable
for over 72 h with no apparent release (<2%), while DOPG:Chol liposomes
released 7.5% of the encapsulated rhodamine B. On the other hand, both lipo-
some formulations released 17% of their content at pH 5.5. These results indicate
that both formulations showed stability at both pH conditions and in serum
containing PBS medium.
In addition, Nile red was used as a hydrophobic model molecule to observe the
encapsulation capacities of PA integrated and bare liposomes. Since the hydro-
phobic dye encapsulation was performed aer liposomes were prepared, free Nile
red was rst removed and encapsulated material was quantied by the calibration
curve aer destruction of liposomes in ethanol. Due to a slightly lower polarity
and larger lipophilic surface area, PA integrated liposomes entrapped four times
more Nile red with respect to the bare liposomes (Table S2†). The number of
encapsulated dye molecules per liposome was found to be 7.9  105 and 3.13 
106 for bare and PA integrated liposomes, respectively.
In vitro uptake of model dyes entrapped in liposomes
In order to evaluate the biocompatibility of liposomal formulations, MCF7 cells
were treated with bare liposomes, PA integrated liposomes and PA molecules.
Peptide amphiphile molecules did not cause signicant change in cell viability in
either the liposomal or free form aer 4 h and 24 h of treatment (Fig. S5†). On the
other hand, liposomal formulations had a positive eﬀect on the cell proliferation
aer 24 h, which could be due to the use of liposomes as a nutritional source
by cells.
The delivery eﬃciency of liposomes was evaluated by measuring the amount
of uorescent reagent taken up by MCF7 cells. Two dyes, hydrophilic rhodamine
B and hydrophobic Nile red were separately used as model dyes. Tracking
rhodamine B uptake is an eﬃcient way to quantify liposomal uptake rates.26,27
Upon 3 h of treatment with equal amounts of rhodamine B, the use of PA inte-
grated liposomes resulted in ve times more rhodamine B uptake compared to276 | Faraday Discuss., 2013, 166, 269–283 This journal is ª The Royal Society of Chemistry 2013
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View Article Onlineboth native liposomes and free rhodamine B (p < 0.001) (Fig. 1). Although it was
previously reported that the liposome size and their in vitro uptake rates are
inversely proportional,28 we observed that cell penetrating PA integrated lipo-
somes, which are larger than bare liposomes, showed enhanced delivery of
hydrophilic dye into the MCF7 cells. On the other hand, no signicant diﬀerence
was detected between the uptake of free rhodamine B and rhodamine B in bare
liposomes. These results reveal that the noncovalent integration of cell pene-
trating PAs into liposomes improved cellular uptake of hydrophilic cargo by
facilitating the liposome internalization. The cationic guanidine group of the
arginine side chain has previously been shown to be important for the membrane
translocation properties,29 and might have enhanced the internalization of PA
functionalized liposomes.
Several anticancer drugs including paclitaxel, cyclosporine, and amphoter-
icin B have hydrophobic properties and are absorbed in the membrane of a
liposome in addition to its lumen.30 Nile red is a hydrophobic uorescent dye
and is therefore a suitable model molecule to track the behaviour of the lipo-
philic cargo in liposomes. MCF7 cells were treated with free Nile red, or Nile red
encapsulated native or PA integrated liposomes for 3 h. The cells were imaged
and cellular extracts were analysed by uorescence spectroscopy. The uores-
cence images indicated that DOPG:Chol liposomes facilitated the internaliza-
tion of the hydrophobic cargo upon PA modication in contrast to unmodied
liposomes (Fig. 2). Upon quantication of the relative uptake levels by Nile red
extraction, PA integrated DOPG:Chol liposomes showed 30% increase in uptake
(p < 0.001) compared to bare liposomes (Fig. 2). The uptake level of free Nile red
was signicantly lower than that of both PA modied and bare liposomes.
Considering the number of Nile red molecules per liposome, a higher encap-
sulation capacity of PA integrated liposomes enables the administration of
fewer liposomes compared to bare liposomes for delivering an equal concen-
tration of Nile red (Table S2†). Therefore, our results suggest that PA integration
enhances the hydrophobic Nile red uptake not only by increasing the encap-
sulation capacity of DOPG:Chol liposomes but also by enhancing liposome
internalization.Fig. 1 Uptake of 4.5 mM rhodamine B within DOPG:Chol and DOPG:Chol:PA liposomes by MCF7 breast
cancer cells after 3 h of treatment. Free rhodamine B was used as a control. The acquired signals were
normalized to the protein concentration of the samples to calculate the relative uptake value. (*** stands
for p < 0.0001) (n ¼ 4).
This journal is ª The Royal Society of Chemistry 2013 Faraday Discuss., 2013, 166, 269–283 | 277
Fig. 2 Uptake of 10 mM Nile red by MCF7 cells. Nile red was administrated in free or liposome
encapsulated form for 3 h. Top: ﬂuorescence microscopy images of cells following liposomal DOPG:Chol,
DOPG:Chol:PA and free Nile red administration. Bottom: quantitative representation of Nile red taken up
by tumor cells after 3 h of incubation. The acquired signals were normalized to the protein concentration
of the samples. (*** stands for p < 0.001) (n ¼ 4).
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View Article OnlineThe eﬀect of the amount of peptide incorporated into the liposomal system on
the cellular uptake was also investigated by using a similar formulation
(DOPG:Chol:PA) with less amount of peptide (7.5 : 8 : 0.5). The physical proper-
ties of the liposomes such as size and zeta potential were measured and the
peptide amphiphile coverage and number of peptide amphiphiles per liposome
were calculated (Table S3†). The amount of peptide did not signicantly change
the size and zeta potential of the liposome while the number of peptide amphi-
phile molecules integrated into one liposome decreased to 2706 from 4568.
Liposomes containing less amount of PA exhibited similar encapsulation capacity
to liposomes containing a higher amount of PA. The number of encapsulated Nile
red molecules per liposome was found to be 3.04  106. Upon quantication of
the relative uptake levels by Nile red extraction, PA integrated DOPG:Chol lipo-
somes demonstrated enhanced uptake compared to bare liposomes as the
number of cell penetrating peptide amphiphile molecules increased (Fig. S6†). It
has previously been demonstrated that the intracellular delivery of liposomes
containing cell-penetrating peptides was enhanced with an increased number of
peptide molecules attached onto the liposomes.31,32Encapsulation of doxorubicin-HCl and paclitaxel
The eﬀect of arginine-rich cell penetrating peptide integration on liposomal
delivery was investigated by using two well-known cancer drugs, hydrophilic
doxorubicin-HCl and hydrophobic paclitaxel. For doxorubicin-HCl and paclitaxel
encapsulation, 1 : 25 and 1 : 15 (w/w) liposomal content to drug ratios were used,278 | Faraday Discuss., 2013, 166, 269–283 This journal is ª The Royal Society of Chemistry 2013
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View Article Onlinerespectively. Both the liposome formulation and the liposome preparation
methods are important parameters aﬀecting the encapsulation capacity.33,34
Therefore, the eﬀect of peptide integration on the amount of encapsulated
doxorubicin-HCl was determined by using uorescence spectroscopy, and pacli-
taxel carrying liposomes were analysed by HPLC to quantify the entrapment
eﬃciency. The results are presented in Tables S4 and S5†. The native and PA
integrated liposomes encapsulated 0.26 mM and 0.23 mM doxorubicin-HCl,
respectively.
Paclitaxel is a known hydrophobic drug, which is currently used dissolved in a
50 : 50 (v/v) mixture of Cremophor and ethanol. Drawbacks of current formu-
lation, such as Cremophor associated serious side eﬀects and the possible
precipitation of paclitaxel in aqueous media, require the development of new
carrier systems with high encapsulation eﬃciency.35 Similar to Nile red encap-
sulation results, PA integrated liposomes showed higher encapsulation eﬃciency
for paclitaxel compared to bare liposomes. Less hydrophobic character of the PA
integrated liposome membrane compared to bare liposomes might be the reason
for enhanced encapsulation of paclitaxel. The concentration of encapsulated
paclitaxel was found to be 92 mM in native liposomes and 117 mM in PA integrated
liposomes (Table S5†). When the number of encapsulated molecules per lipo-
some for each drug was calculated, the PA integrated liposomes showed superior
encapsulation eﬃciency over bare liposomes (Tables S4 and S5†).In vitro tumor inhibitory eﬀect of native and PA integrated drug loaded
liposomes
The in vitro therapeutic eﬀects of anticancer drug loaded PA integrated and PA
free DOPG:Chol liposomes were evaluated via cytotoxicity assays and determi-
nation of cell proliferation rates by using the MCF7 breast cancer cell line. The
activity of doxorubicin-HCl on tumor cells is mainly mediated by oxidative DNA
damage and topoisomerase II inhibition in the nucleus, which results in
apoptosis.36 Here, the dose responses of doxorubicin-HCl loaded DOPG:Chol
liposomes and free doxorubicin-HCl were evaluated by quantication of the total
metabolic activity aer 24 h of exposure (Fig. 3). Half maximal inhibitory
concentration (IC50) values were calculated as 2.58 mM, 2.48 mM and 0.88 mM for
doxorubicin-HCl loaded DOPG:Chol, DOPG:Chol:PA liposomes and free drug
(Fig. S7†). When used at low concentrations, liposomal doxorubicin-HCl has
previously been shown to have lower toxicity compared to free doxorubicin.37 The
liposomal doxorubicin-HCl system is taken into the cell by endocytosis and is
slowly released into the cytoplasm, which results in an increased number of
barriers and slower therapeutic eﬀect in contrast to free doxorubicin-HCl.24,37
These results show that increasing the concentration of doxorubicin-HCl
enhanced the eﬀectiveness of the liposome–doxorubicin-HCl systems.
Following dose response studies, the time dependent response of MCF7 cells
to doxorubicin treatment was evaluated at 1, 3 and 6 h exposure times (Fig. 3). For
the free and liposomal doxorubicin-HCl systems, the viability decreased with
increasing exposure time. Aer 1 h of treatment, we observed that PA modied
DOPG:Chol liposomes and free doxorubicin-HCl had almost two fold lower
viability with respect to PA free DOPG:Chol liposomes (p < 0.001). The higher
cytotoxicity of PA integrated liposomal doxorubicin-HCl demonstrated anThis journal is ª The Royal Society of Chemistry 2013 Faraday Discuss., 2013, 166, 269–283 | 279
Fig. 3 Time response of MCF7 cells to 1, 3 and 6 h of 10 mM free or liposomal doxorubicin-HCl
treatment. Following administration, cells were incubated in fresh media for further 24 h and the
viability of the cells was measured. (*** stands for p < 0.001, ** stands for p < 0.01, * stands for p < 0.05)
(n ¼ 4).
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View Article Onlineimprovement in the delivery eﬃciency caused by arginine-rich cell penetrating
peptide incorporation into native liposomes. Bare liposomes exhibited a dramatic
decrease in cell viability when the exposure time was increased from 1 h to 3 h
( p < 0.001) while PA integrated liposomes and free doxorubicin-HCl did not show
any signicant diﬀerence. However, at 6 h of treatment, there was a signicant
decrease in cell viability for PA integrated liposomal doxorubicin-HCl and free
doxorubicin-HCl (p < 0.001 for DOPG:Chol:PA and p < 0.01 for free doxorubicin-
HCl) compared to shorter exposures. A statistically signicant cell viability
decrease was also observed for PA free liposomes (p < 0.05) aer 6 h of drug
exposure compared to shorter durations.
In addition, paclitaxel was used as a hydrophobic drug to examine the in vitro
therapeutic eﬀect of liposome encapsulated and free drug. Paclitaxel mainly acts
as a G2/M cell cycle inhibitor and impedes cell proliferation by inhibiting
microtubule dynamics.38We investigated the responses of MCF7 cells against free
and liposomal paclitaxel in both time and dose dependent manners by deter-
mining cell proliferation inhibition. Dose dependent cytotoxicity studies
demonstrated that PA integrated liposomes resulted in an enhanced therapeutic
eﬀect at all doses from 0.2 nM to 2 mM of paclitaxel (p < 0.001) compared to free
paclitaxel (Fig. 4). As a result of 10 mM paclitaxel administration with DOPG:Chol
and DOPG:Chol:PA, the viability of MCF7 cells was equally aﬀected and decreased
to about 50%. At this concentration, the inhibitory eﬀect was two times higher for
both PA integrated and native liposomes than that of free paclitaxel. The results
reveal that both liposomes caused proliferation inhibition since the average
doubling time of the MCF7 cells was 24 h and the number of untreated cells
(control group) was doubled aer 24 h.39 These results show that enhanced cell
growth inhibition via PA incorporated liposomes was observed for paclitaxel
treatment with various concentrations. In addition, the response of MCF7 cells
was evaluated by administering 30 mM of paclitaxel at 1 h, 3 h and 6 h. Both native
and PA modied liposomes had time dependent cytotoxic response (Fig. 5). At280 | Faraday Discuss., 2013, 166, 269–283 This journal is ª The Royal Society of Chemistry 2013
Fig. 4 Dose response of MCF7 cells against free paclitaxel and paclitaxel loaded DOPG:Chol and
DOPG:Chol:PA liposomes within a spectrum of ﬁnal concentrations ranging from 0.2 nM to 10 mM. After
24 h exposure to paclitaxel, the viability of the cells was measured. Cell proliferation in the presence of
DOPG:Chol:PA liposomes was signiﬁcantly lower (p < 0.001) than both DOPG:Chol liposomes and free
paclitaxel at all paclitaxel concentrations except 10 mM. At 10 mMpaclitaxel concentration, free paclitaxel
showed a signiﬁcantly lower eﬀect compared to both DOPG:Chol and DOPG:Chol:PA liposomes ( p <
0.001) (n ¼ 4).
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View Article Onlinelonger liposomal paclitaxel exposure, cell viability decreased by 25% in PA inte-
grated liposomes while it did not change and remained at 75% in native lipo-
somes. In the case of free paclitaxel, the therapeutic eﬀect was not improved and
the cell viability was close to that of native liposomes. Overall, our results suggest
that PA integrated liposomes provide a more eﬃcient delivery method for pacli-
taxel compared to PA-free liposomes and free drug.Fig. 5 Time response of MCF7 cells to 1, 3 and 6 h of 30 mM free or liposomal paclitaxel exposure.
Cytotoxic eﬀects of paclitaxel loaded DOPG:Chol and DOPG:Chol:PA liposomes. All results were
normalized to the viability level of nontreated cells. (*** stands for p < 0.001, ** stands for p < 0.01, *
stands for p < 0.05) (n ¼ 4).
This journal is ª The Royal Society of Chemistry 2013 Faraday Discuss., 2013, 166, 269–283 | 281
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View Article OnlineConclusions
In summary, we developed a liposomal carrier system, which was decorated with
cell penetrating arginine-rich peptide amphiphile molecules via the use of
amphipathicity as an alternative functionalization method to chemical linkage.
The resulting liposomes were found to be nontoxic and had high encapsulation
capacity for both hydrophobic (Nile red) and hydrophilic (rhodamine B) model
dyes with very slow in vitro release rates. Fluorescence measurements showed that
the integration of the cell penetrating peptide amphiphiles to liposomes
enhanced the uptake of model reagents by MCF7 breast cancer cells with respect
to native liposomes as well as free reagents. The therapeutic eﬀects of common
cancer drugs, doxorubicin-HCl and paclitaxel, were studied in vitro. Cytotoxicity
caused by the drug–liposome systems was observed to depend on the drug
concentration. Time response studies showed that cell penetrating PA incorpo-
ration into DOPG:Chol liposomes improved liposomal delivery and enhanced the
therapeutic eﬀect of both hydrophilic (doxorubicin-HCl) and hydrophobic
(paclitaxel) anticancer agents on MCF7 breast cancer cells. By use of this non-
covalent functionalization technique, peptide epitopes can be easily incorporated
into liposomal systems in one step without the need for any additional chemical
reagents and the loss of activity is minimized by avoiding anchorage. Several
peptide signals with diﬀerent bioactive properties can be used to enhance the
eﬀectiveness of liposomal carriers, which have great potential in cancer treatment
and imaging.
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